NEWBURYPORT, MA--(Marketwire - May 30, 2012) -
PCI Synthesis, Inc. (www.pcisynthesis.com
), a 12-year-old custom chemical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products, today announced that industry veteran Alexander Tretyakov has joined the company as Vice President of Research and Development.
In this role, Tretyakov will provide technical leadership across the company, specifically in creating de novo synthetic schemes and approaches. He will liaise with customers on the technical end, and provide oversight and professional development opportunities for the research and development department.
In making the announcement, Ed Price, President of PCI, said, "Alex brings more than 24 years of experience spanning a diverse range of organic chemistries. He has deep background in manufacturing cost analysis, organic synthesis, synthetic route design, chemical process development and more. This expertise, coupled with his experience in driving significant business growth as both an entrepreneur as well as a corporate executive in the chemical manufacturing industry, will be invaluable as PCI continues to grow."
Prior to joining PCI, Tretyakov worked for more than nine years at Cambridge Major Laboratories, a leading global chemistry outsourcing partner to the pharmaceutical and biotechnology industries, where he served most recently as Vice President of R&D. Previously he launched Omega Engineering, providing custom synthesis solutions to the pharmaceutical and fine chemical industries. Prior to that he held increasingly responsible roles as plant chemist, pilot plan operations supervisor, scientist and chemical engineer at various chemical manufacturers.
Tretyakov earned a B.S. in chemical engineering and a M.S. in organic chemistry at Leningrad Chemical Pharmaceutical Institute in Leningrad, Russia. He earned his Ph.D. in organic chemistry from the University of Oklahoma.
About PCI Synthesis
PCI Synthesis is a 12-year-old custom chemical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products. A contract manufacturing organization (CMO), PCI provides emerging and mid-sized pharmaceutical companies access to the expertise needed to develop and manufacture complex small molecules and APIs used in generic pharmaceuticals. To learn more about PCI Synthesis, its proprietary NCE development activities and process R&D capabilities please visit www.pcisynthesis.com.